Lake Street Private Wealth LLC Has $3.22 Million Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Lake Street Private Wealth LLC grew its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 28.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 133,168 shares of the company's stock after acquiring an additional 29,721 shares during the quarter. Lake Street Private Wealth LLC owned about 0.06% of Hims & Hers Health worth $3,220,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. GAMMA Investing LLC increased its position in Hims & Hers Health by 2,173.7% in the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company's stock valued at $54,000 after acquiring an additional 2,152 shares during the period. Quest Partners LLC grew its stake in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company's stock worth $81,000 after purchasing an additional 807 shares in the last quarter. CWM LLC increased its holdings in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after purchasing an additional 1,054 shares during the period. Quarry LP raised its stake in shares of Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company's stock valued at $113,000 after purchasing an additional 2,913 shares in the last quarter. Finally, Amalgamated Bank lifted its holdings in Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company's stock worth $133,000 after purchasing an additional 2,354 shares during the period. Institutional investors own 63.52% of the company's stock.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the company's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total value of $3,943,981.44. Following the transaction, the chief executive officer now directly owns 67,015 shares of the company's stock, valued at approximately $1,399,273.20. This represents a 73.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $24.44, for a total value of $283,039.64. Following the sale, the chief financial officer now owns 118,077 shares of the company's stock, valued at approximately $2,885,801.88. This represents a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,080,208 shares of company stock valued at $29,106,823. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Trading Down 0.5 %

Shares of HIMS traded down $0.14 during midday trading on Friday, hitting $27.80. The stock had a trading volume of 18,842,443 shares, compared to its average volume of 9,739,798. Hims & Hers Health, Inc. has a fifty-two week low of $8.14 and a fifty-two week high of $35.02. The business has a 50-day simple moving average of $27.68 and a two-hundred day simple moving average of $21.85. The firm has a market cap of $6.07 billion, a P/E ratio of 63.19 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company's quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.04) EPS. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on HIMS. BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a "buy" rating and a $35.00 target price on the stock. Bank of America cut shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their price objective for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Citigroup cut Hims & Hers Health from a "neutral" rating to a "sell" rating and boosted their target price for the stock from $24.00 to $25.00 in a report on Friday, January 10th. Piper Sandler increased their price target on Hims & Hers Health from $21.00 to $24.00 and gave the company a "neutral" rating in a research note on Monday, January 6th. Finally, Morgan Stanley initiated coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $42.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.